What is the equivalent dose of semaglutide (Wegovy) for 5 milligrams of tirzepatide (Zepbound)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

The equivalent dose of Wegovy (semaglutide) to 5 mg of Zepbound (tirzepatide) is approximately 0.5 mg of Wegovy. These medications work similarly as injectable treatments for weight management, but they target different receptors. Zepbound is a dual GIP/GLP-1 receptor agonist, while Wegovy is a GLP-1 receptor agonist only. This difference in mechanism explains why Zepbound may produce somewhat greater weight loss at equivalent therapeutic doses, as shown in a study comparing tirzepatide and semaglutide 1. Both medications are typically started at lower doses and gradually increased over several weeks to minimize gastrointestinal side effects. If switching between these medications, it's essential to consult with your healthcare provider to determine the appropriate dose conversion and titration schedule, as individual responses may vary. Your provider might recommend starting at a lower dose than the equivalent when switching to ensure tolerability, especially since these medications can cause side effects like nausea, vomiting, and diarrhea during the adjustment period.

Some key points to consider when using these medications include:

  • The efficacy and safety of tirzepatide compared to semaglutide have been evaluated in several studies, including a systematic review and network meta-analysis 1 and a Bayesian network meta-analysis 2.
  • Tirzepatide has been shown to be effective in reducing HbA1c and body weight in patients with type 2 diabetes, and also has potential benefits in patients with heart failure with preserved ejection fraction and obesity 3.
  • The cost of these medications is an important consideration, with estimates suggesting that treating 1% of the population with semaglutide or tirzepatide could result in significant annual costs 4.
  • However, the cost-benefit ratio of these medications may ultimately be favorable, given their potential to improve health outcomes and reduce the burden of obesity-related complications.

Overall, when considering the use of Wegovy or Zepbound for weight management, it's essential to weigh the potential benefits and risks, and to consult with a healthcare provider to determine the most appropriate treatment plan.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.